Subtype
Prostate Adenocarcinoma
CI-CAN-00003766PRADExplore in graph →
133 active trials1 approved drugs3 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003766PRADExplore in graph →
Clinical trials
433 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (71)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03204812 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2024 |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01985828 | CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | completed | N/A | 83 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02099864 | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | completed | Phase 2 | 36 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | terminated | Phase 1 | 60 | University of ChicagoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06184464 | Prostatic Size Reduction Following of Leuprorelin Acetate(PROSTSIZE) | recruiting | — | 40 | Consorci Sanitari de TerrassaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06518226 | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer(TURBO) | recruiting | N/A | 160 | UMC UtrechtOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT02830165 | Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | completed | N/A | 11 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04694924 | Prospective Prostate Cancer and Patient-reported Outcomes Registry(Prosquare) | recruiting | — | 5,000 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT02163317 | Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer | completed | N/A | 12 | Case Comprehensive Cancer CenterOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03177460 | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06387238 | Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer | unknown | N/A | 150 | Peking University First HospitalOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06299046 | Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study(UROBLOOD01) | completed | — | 194 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06292897 | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression(OBESITA'&PCa) | recruiting | — | 25 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients(HIIT PCa) | withdrawn | N/A | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04909294 | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma(STEREO-RML) | active not recruiting | N/A | 68 | Centre Georges Francois LeclercOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03698370 | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | completed | Phase 2 | 27 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01394263 | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | completed | Phase 3 | 59 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT01697384 | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | completed | Phase 3 | 138 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | withdrawn | — | 0 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03518853 | Short Course Radiotherapy for Localized Prostate Cancer(SHORT) | completed | N/A | 30 | Tata Medical CenterOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03113617 | 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | completed | Phase 2 | 44 | Andrei IagaruOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT00915122 | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate | completed | Phase 1 / Phase 2 | 81 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT05197257 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | completed | Phase 3 | 39 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03396874 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | completed | Phase 2 | 1,435 | University of MichiganOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT00020046 | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03830164 | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01949337 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | unknown | Phase 3 | 1,311 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 28, 2023 | clinicaltrials |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05919524 | SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer(SAFO) | unknown | N/A | 27 | Almudena ZapateroOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06029088 | Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer | completed | — | 616 | Ankara Etlik City HospitalOTHER_GOV | 1 | Sep 8, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04914195 | Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | completed | Phase 3 | 155 | Bharat Serums and Vaccines LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT01913717 | Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02672449 | Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy(THRIP) | terminated | N/A | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT01411332 | Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial(HEIGHT) | completed | N/A | 18 | University of MiamiOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 23, 2024source: clinicaltrials